Menu

U.K. Moves Forward With Three-Parent IVF

The country’s fertility regulator has approved the first application to carry out mitochondrial replacement therapy, which uses biological material from two women and one man to create an embryo.

Mar 20, 2017
Bob Grant

PIXABAYMitochondrial replacement therapy (MRT), also known as three-parent in vitro fertilization, is set to make its way to the clinic in the U.K. Last week (March 16), the country’s Human Fertilisation and Embryo Authority (HFEA) approved the first application for license to perform the procedure. The HFEA granted a license to Newcastle University, where researchers have been studying the technique for several years.

“I can confirm today that the HFEA has approved the first application by Newcastle Fertility at Life for the use of mitochondrial donation to treat patients,” HFEA Chair Sally Cheshire told CNN. “Patients will now be able to apply individually to the HFEA to undergo mitochondrial donation treatment at Newcastle, which will be life-changing for them, as they seek to avoid passing on serious genetic diseases to future generations.”

According to Science, Newcastle has said that numerous families have expressed interest in MRT.

MRT, a technique that has stirred some controversy in bioethics circles, involves the transfer of sperm and/or oocyte pronuclei from a fertilized egg before the zygote forms. The protocol is a way for women that carry the potential for mitochondrial diseases to avoid passing suck maladies on to their offspring.

Last year, a US doctor working in Mexico claimed to have successfully birthed the world’s first baby born using MRT.

July 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) July 15, 2019 announced the launch of its Bio-Plex Pro Human Immunotherapy Panel 20-plex, a multiplex immunoassay that offers a targeted approach for Immunotherapy Research.
DeNovoMAX - NRGene's new genomics tool to meet a major agbio need:
DeNovoMAX - NRGene's new genomics tool to meet a major agbio need:
NRGene has launched a new product that aims to empower breeding and maximize agricultural yield as part of the Denovo assembly product suite offered by the company.
Overcoming the Efficiency Challenge in Clinical NGS
Overcoming the Efficiency Challenge in Clinical NGS
Download this white paper to see how an ECS lab serving a network of more than 10,000 healthcare providers integrated QIAGEN Clinical Insight (QCI) Interpret to significantly reduce manual variant curation efforts and increase workflow efficiency by 80%!
Veravas Launches Product Portfolio to Mitigate Biotin Interference and Improve Diagnostic Assay Accuracy
Veravas Launches Product Portfolio to Mitigate Biotin Interference and Improve Diagnostic Assay Accuracy
Veravas, Inc., an emerging diagnostic company, launched a portfolio of products that can improve the accuracy of current diagnostic test results by helping laboratory professionals detect and manage biotin interference in patient samples with VeraTest Biotin and VeraPrep Biotin.